Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: An open trial of nefazodone

Journal of Clinical Psychiatry

Volumn 60, Issue 4, 1999, Pages 226-231

  Elliott, Andrew J ^a,b   Russo, Joan ^a   Bergam, Karen ^a   Claypoole, Keith ^a   Uldall, Karina K ^a   Roy Byrne, Peter P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; INDINAVIR; NEFAZODONE; NELFINAVIR; PAROXETINE; RITONAVIR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HAMILTON SCALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; VERTIGO;

EID: 0032908843     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0404     Document Type: Article

References (32)

1. Brown GR, Rundell JR, McManis SE, et al. Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med 1992;54: 588-601
2. Perkins DO, Stern RA, Golden RN, et al. Mood disorders in HIV infections: prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry 1994;151:233-236
3. Rosenberger PH, Bornstein RA, Nasrallah RH, et al. Psychopathology in human immunodeficiency virus infection: lifetime and current assessment. Compr Psychiatry 1993;34:150-158
4. Robins LN, Helzer JD, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41: 949-958
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51: 8-19
6. Elliott AJ, Uldall KK, Bergam K, et al. A randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998;155:367-372
7. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995;56(suppl 6):37-42
8. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56 (suppl 6):3-11
9. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57 (suppl 2):53-62
10. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996;57(suppl 2): 46-52
11. Spitzer RL, Williams JBW, Gibbon M, et al. Structured Clinical Interview for DSM-IV. New York, NY: Biometric Research, New York State Psychiatric Institute; 1994
12. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
13. Hamilton M. The assessment of anxiety. In: Trimble MR, ed. Benzodiazepines Divided. New York, NY: John Wiley & Sons; 1983:33-43
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
15. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
16. Rabkin JG, Markowitz JS, Ocepek-Welikson K, et al. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol 1992;12:3-10
17. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983;13:595-605
18. Mulder J, McKinney N, Christopherson C, et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300
19. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-18
20. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855
21. Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994;151:516-523
22. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164: 802-805
23. Segraves RT. Overview of sexual dysfunction complicating the treatment of depression. J Clin Psychiatry Monograph 1992;10(2):4-10
24. Norvir [package insert]. North Chicago, Ill: Abbott Laboratories; 1997
25. Denissen JF, Grabowski BA, Johnson MR, et al. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ACT-538) in rats, dogs, and humans. Drug Metab Dispos Biol Fate Chem 1997;25:489-501
26. Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997;53:608-636
27. Serzone [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 1997
28. Feighner JP, Pambakian R, Fowler RC, et al. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989;25:219-221
29. Cohn CK, Robinson DS, Roberts DL, et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996;57(suppl 2): 15-18
30. Shader RI, Greenblatt DJ. Protease inhibitors and drug interactions: an alert. J Clin Psychopharmacol 1996;16:343-344
31. AIDS Clinical Trials Group (ACTG). 388 Drug Information Sheet. Research Triangle Park, NC: Glaxo-Wellcome; 1997
32. Wagner GJ, Rabkin JG, Rabkin R. A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients. Compr Psychiatry 1996;37:402-408